博济医药：获得中药创新药“卿芷软膏”临床试验批准通知书

Core Viewpoint - The announcement by Boji Pharmaceutical (300404.SZ) regarding the approval of "Qingzhi Ointment" for clinical trials by the National Medical Products Administration indicates a step forward in the company's drug development efforts, although it is not expected to significantly impact the company's financial performance in the short term [1]. Group 1: Drug Development - Boji Pharmaceutical's wholly-owned subsidiary, Guangzhou Boji New Drug Clinical Research Center Co., Ltd., has received the clinical trial approval for "Qingzhi Ointment," classified as a Class 1 innovative traditional Chinese medicine [1]. - The ointment is intended for the treatment of knee osteoarthritis with symptoms of wind-cold-dampness, focusing on dispelling wind, overcoming dampness, relieving cold, promoting circulation, and alleviating pain [1]. Group 2: Financial Impact - The company stated that the approval of the drug will not have a significant impact on its operating performance [1]. - The company will fulfill its information disclosure obligations based on the progress of the drug development [1]. Group 3: R&D Uncertainties - The company acknowledged the long development cycle and multiple stages involved in drug research and development, highlighting the inherent uncertainties in the process [1].